The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV is published in an electronic format and updated as relevant changes in prevention and treatment recommendations occur. 

All updates are developed by the subject matter groups listed in Appendix B. (Changes in group composition also are posted regularly.) These updates are reviewed by the editors and relevant outside reviewers before the guideline is altered. Major revisions within the last 6 months are as follows: 

Mycobacterium tuberculosis 

• Recommended a 4-month regimen of daily rifapentine, isoniazid, pyrazinamide, and moxifloxacin as an alternative treatment for active pulmonary tuberculosis (TB) in people receiving efavirenz-based antiretroviral therapy. 
• Recommended a regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (“BPaLM”) as the preferred treatment for rifampin-resistant TB. 

For a list of recent updates, please see What's New in the Guidelines. To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infections Guidelines section of Clinical Info’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.    

Clinical Info welcomes your feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Please send your comments with the subject line “Adult and Adolescent Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by May 21, 2024.